Sahakyan Y, Erman A, Bhojani N, Chughtai B, Zorn KC, Sander B, Elterman DS. Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia: A Canadian healthcare payer perspective. CUAJ [Internet]. 2022 Dec. 6 [cited 2024 Apr. 25];17(4):103-10. Available from: https://cuaj.ca/index.php/journal/article/view/8045